Cargando…

The factors associated with chronic benzodiazepine use in bipolar patients

INTRODUCTION: Benzodiazepines (BZD) are widely used in patients with bipolar disorder (BD) and their effectiveness is well documented. Therefore, there are major risks associated with BZD use including abuse and dependence. Those risks can be related to the patients’chacteristics, the particularitie...

Descripción completa

Detalles Bibliográficos
Autores principales: Charfi, N., Abdallah, M. Ben, Omri, S., Smaoui, N., Feki, R., Thabet, J. Ben, Zouari, L., Bouali, M. Maalej, Maalej, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528342/
http://dx.doi.org/10.1192/j.eurpsy.2021.539
_version_ 1784801278936743936
author Charfi, N.
Abdallah, M. Ben
Omri, S.
Smaoui, N.
Feki, R.
Thabet, J. Ben
Zouari, L.
Bouali, M. Maalej
Maalej, M.
author_facet Charfi, N.
Abdallah, M. Ben
Omri, S.
Smaoui, N.
Feki, R.
Thabet, J. Ben
Zouari, L.
Bouali, M. Maalej
Maalej, M.
author_sort Charfi, N.
collection PubMed
description INTRODUCTION: Benzodiazepines (BZD) are widely used in patients with bipolar disorder (BD) and their effectiveness is well documented. Therefore, there are major risks associated with BZD use including abuse and dependence. Those risks can be related to the patients’chacteristics, the particularities of BD and the prescribers. OBJECTIVES: To determine the factors associated with chronic use of BZD in patients with BD. METHODS: We conducted a cross-sectional, descriptive and analytical study among a sample of patients with BD (DSM-5) followed in psychiatric outpatient of Hedi Chaker university hospital in Sfax. We used the Benzodiazepine Cognitive Attachment Scale (ECAB) to determine dependent patients RESULTS: Among the 61 included patients, 50 (82%) had a chronic use of BZD (> 3 months). They had a mean age of 49.3 years (± 14.02 years) and a low socio-economic level in 44%. The type of BD was dominated by type II (66%). Initial episode type was depressive in 78%. The average number of depressive episodes was 2.92±2.3. A rate of 65.5% of patients have already attempted BZD withdrawal. Chronic BZD use was significantly correlated with BZD dependence (p=0.000), low socioeconomic level (p=0.04), depressive type of the initial episode (p=0.011), the depressive recurrence (p=0.000) and the absence of any attempt to discontinue BZD (p=0.011). CONCLUSIONS: Chronic use of BZD in patients with BD is prevalent. In order to minimize this problem in this population, it is important to enhance programs to improve psychiatrist-prescribing behavior and to use cognitive-behavioral therapies in combination with medication to help withdrawal.
format Online
Article
Text
id pubmed-9528342
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95283422022-10-17 The factors associated with chronic benzodiazepine use in bipolar patients Charfi, N. Abdallah, M. Ben Omri, S. Smaoui, N. Feki, R. Thabet, J. Ben Zouari, L. Bouali, M. Maalej Maalej, M. Eur Psychiatry Abstract INTRODUCTION: Benzodiazepines (BZD) are widely used in patients with bipolar disorder (BD) and their effectiveness is well documented. Therefore, there are major risks associated with BZD use including abuse and dependence. Those risks can be related to the patients’chacteristics, the particularities of BD and the prescribers. OBJECTIVES: To determine the factors associated with chronic use of BZD in patients with BD. METHODS: We conducted a cross-sectional, descriptive and analytical study among a sample of patients with BD (DSM-5) followed in psychiatric outpatient of Hedi Chaker university hospital in Sfax. We used the Benzodiazepine Cognitive Attachment Scale (ECAB) to determine dependent patients RESULTS: Among the 61 included patients, 50 (82%) had a chronic use of BZD (> 3 months). They had a mean age of 49.3 years (± 14.02 years) and a low socio-economic level in 44%. The type of BD was dominated by type II (66%). Initial episode type was depressive in 78%. The average number of depressive episodes was 2.92±2.3. A rate of 65.5% of patients have already attempted BZD withdrawal. Chronic BZD use was significantly correlated with BZD dependence (p=0.000), low socioeconomic level (p=0.04), depressive type of the initial episode (p=0.011), the depressive recurrence (p=0.000) and the absence of any attempt to discontinue BZD (p=0.011). CONCLUSIONS: Chronic use of BZD in patients with BD is prevalent. In order to minimize this problem in this population, it is important to enhance programs to improve psychiatrist-prescribing behavior and to use cognitive-behavioral therapies in combination with medication to help withdrawal. Cambridge University Press 2021-08-13 /pmc/articles/PMC9528342/ http://dx.doi.org/10.1192/j.eurpsy.2021.539 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Charfi, N.
Abdallah, M. Ben
Omri, S.
Smaoui, N.
Feki, R.
Thabet, J. Ben
Zouari, L.
Bouali, M. Maalej
Maalej, M.
The factors associated with chronic benzodiazepine use in bipolar patients
title The factors associated with chronic benzodiazepine use in bipolar patients
title_full The factors associated with chronic benzodiazepine use in bipolar patients
title_fullStr The factors associated with chronic benzodiazepine use in bipolar patients
title_full_unstemmed The factors associated with chronic benzodiazepine use in bipolar patients
title_short The factors associated with chronic benzodiazepine use in bipolar patients
title_sort factors associated with chronic benzodiazepine use in bipolar patients
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528342/
http://dx.doi.org/10.1192/j.eurpsy.2021.539
work_keys_str_mv AT charfin thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT abdallahmben thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT omris thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT smaouin thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT fekir thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT thabetjben thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT zouaril thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT boualimmaalej thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT maalejm thefactorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT charfin factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT abdallahmben factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT omris factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT smaouin factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT fekir factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT thabetjben factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT zouaril factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT boualimmaalej factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients
AT maalejm factorsassociatedwithchronicbenzodiazepineuseinbipolarpatients